Catalent's gross profit for the
three
months ended in Mar. 2024 was $229 Mil. Catalent's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $784 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Catalent's gross profit for the
three
months ended in Mar. 2024 was $229 Mil. Catalent's Revenue for the
three
months ended in Mar. 2024 was $1,074 Mil. Therefore, Catalent's Gross Margin % for the quarter that ended in Mar. 2024 was 21.32%.
Catalent had a gross margin of 21.32% for the quarter that ended in Mar. 2024 => Competition eroding margins
During the past 13 years, the highestGross Margin % of Catalent was 33.82%. The lowest was 18.96%. And the median was 31.88%.
Warning Sign:
Catalent Inc gross margin has been in long-term decline. The average rate of decline per year is -2.6%.
Catalent Gross Profit Historical Data
The historical data trend for Catalent's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Catalent's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalent's Gross Profit Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Catalent's Gross Profit distribution charts can be found below:
* The bar in red indicates where Catalent's Gross Profit falls into.
Catalent Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Catalent's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $784 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Catalent (NYSE:CTLT) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Catalent had a gross margin of 21.32% for the quarter that ended in Mar. 2024 => Competition eroding margins
Catalent Gross Profit Related Terms
Thank you for viewing the detailed overview of Catalent's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTLT has been successfully added to your 